| 摘要 |
<p>Provided herein are drug delivery systems comprising a self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems, parenteral microemulsion formulations, and nanosuspension formulations suitable for oral and/or parenteral delivery to a subject. The emulsion based drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. The nanosuspension based drug delivery system may comprise a benzimidazole derivative, e.g., mebendazole, and surface stabilizers, such as block copolymer(s), e.g., Pluronic F108, and surfactant(s), e.g., Tvveen 80, and, optionally, water. Provided are methods for defining nanosuspensions of a benzimidazole derivative as having maximum therapeutic efficacy for a treatment regimen by adjusting and/or selecting particles size(s) based on pharmacokinetic parameters of the derivative in the tissue. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition and for treating a cancer by using the microemulsion and nanosuspension formulation(s) described herein.</p> |
